CORT - Corcept Therapeutics Incorporated
NEXT EARNINGS:
May 4, 2026
EPS Est: $-0.11
|
Rev Est: $186.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$68.40
DETAILS
HIGH:
$100.00
LOW:
$30.00
MEDIAN:
$67.00
CONSENSUS:
$68.40
UPSIDE:
97.46%
Market Cap:
3.68B
Volume:
1,243,804
Avg Volume:
2,257,823
52 Week Range:
28.66-117.33
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.31
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
500
IPO Date:
2004-04-14
EPS (TTM):
0.95
P/E Ratio:
36.27
Revenue (TTM):
761.41M
Total Assets:
836.65M
Total Debt:
6.11M
Cash & Equiv:
120.50M
Rev Growth (5Y):
16.6%
EPS Growth (5Y):
0.6%
FCF Growth (5Y):
-1.2%
ROCE:
9.9%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-24 | $0.20 | $0.33 | -39.4% | $202.1M | $254.9M | -20.7% |
| 2025-11-04 | $0.16 | $0.18 | -11.1% | $207.6M | $255.3M | -18.7% |
| 2025-07-31 | $0.29 | $0.23 | +26.1% | $194.4M | $244.6M | -20.5% |
| 2025-05-05 | $0.17 | $0.17 | 0.0% | $157.2M | $216.7M | -27.4% |
| 2025-02-26 | $0.26 | $0.37 | -29.7% | $181.9M | $200.1M | -9.1% |
| 2024-10-30 | $0.41 | $0.28 | +46.4% | $182.5M | $198.0M | -7.8% |
| 2024-07-29 | $0.32 | $0.23 | +39.1% | $163.8M | $162.1M | +1.1% |
| 2024-05-01 | $0.25 | $0.22 | +13.6% | $146.8M | $141.2M | +4.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 761.41M | 675.04M | 482.38M | 401.86M | 365.98M | 353.87M | 306.49M | 251.25M | 159.20M | 81.32M | 50.29M | 26.55M |
| Net Income | 99.65M | 139.73M | 106.14M | 101.42M | 112.51M | 106.01M | 94.18M | 75.41M | 129.12M | 8.14M | (6.41M) | (31.38M) |
| EPS | 0.95 | 1.35 | 1.02 | 0.95 | 0.97 | 0.92 | 0.82 | 0.60 | 1.14 | 0.07 | -0.06 | -0.31 |
| Total Assets | 836.65M | 840.55M | 621.52M | 583.43M | 423.76M | 571.73M | 412.31M | 311.69M | 220.54M | 68.75M | 51.94M | 34.63M |
| Total Debt | 6.11M | 6.94M | 151,000 | 1.14M | 526,000 | 2.55M | 3.46M | 0 | 0 | 14.66M | 14.96M | 9.42M |
| Cash & Equivalents | 120.50M | 127.67M | 135.55M | 66.33M | 77.62M | 76.19M | 31.27M | 206.76M | 104.03M | 51.54M | 40.44M | 24.25M |
| Operating Cash Flow | 142.00M | 198.07M | 127.04M | 120.32M | 167.89M | 151.97M | 136.12M | 115.67M | 60.94M | 18.39M | 3.13M | (27.38M) |
| Free Cash Flow | 141.78M | 195.90M | 126.90M | 119.91M | 167.42M | 150.73M | 135.03M | 115.37M | 60.52M | 18.20M | 3.11M | (27.55M) |
| FCF per Share | 1.37 | 1.90 | 1.23 | 1.12 | 1.45 | 1.31 | 1.18 | 0.92 | 0.53 | 0.16 | 0.03 | -0.27 |
| Book Value | 647.80M | 679.59M | 506.70M | 501.84M | 375.81M | 523.34M | 371.18M | 275.88M | 190.97M | 41.38M | 18.50M | (3.39M) |
| Cash & ST Investments | 372.15M | 383.33M | 368.22M | 431.67M | 223.53M | 440.70M | 275.96M | 206.76M | 104.03M | 51.54M | 40.44M | 24.25M |
| ROC Equity | 0.15 | 0.21 | 0.21 | 0.20 | 0.30 | 0.20 | 0.25 | 0.27 | 0.68 | 0.20 | -0.35 | N/A |